S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas

Completed · Phase 2

Conditions studied: Sarcoma

In brief

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with advanced soft tissue sarcomas.

Key facts

Study ID
NCT00217620
Run by
National Cancer Institute (NCI)
People needed
51
Starts
2006-03-01
Expected to finish
2012-09-01
Last updated by the study team
2014-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.